Evidence map›Paper›PMID 36788555›Full record

ArticleAnnals of clinical microbiology and antimicrobials2023

Fusion plasmid enhanced the endemic extensively drug resistant Klebsiella pneumoniae clone ST147 harbored bla

Chao Liu, Pengcheng Du, Ping Yang, Ming Lu, Ning Shen

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Chao Liu *Department of Infectious Disease, Peking University Third Hospital, Beijing, China.
Pengcheng Du *Qitan Technology Ltd., Chengdu, China.
Ping Yang *Department of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing, China.
Ming LuDepartment of Infectious Disease, Peking University Third Hospital, Beijing, China. lumingpuh3@163.com.
Ning ShenDepartment of Infectious Disease, Peking University Third Hospital, Beijing, China. shenningputh@163.com.
Peking University Third Hospital · CNPeking University · CN

Funding

Beijing Key Clinical Specialty Program 010071National Natural Science Foundation of China 82200012
6 · The paper itself

Abstract

backgroundKlebsiella Pneumoniae (Kp) sequence type (ST) 147 has emerged globally and spread rapidly, particularly the extensively drug resistant (XDR) isolates. However, the infections caused by this subtype is rare reported in China for now. The clinical, microbiological and genomic characteristics are unclear.

methodsA systemic retrospective study was conducted in a Chinese tertiary hospital. Clinical information of the infection cases was collected, and whole-genome sequencing and phenotypic experiments were performed on the ST147 isolates. The resistance and virulence genes were identified, and the plasmids harboring these genes were further studied.

resultsSix ST147 isolates from six patients among 720 available clincial Kp isolates were detected. Notably, two isolates, PEKP4035 and PEKP4265, represented both XDR and hypervirulence by acquiring bla

conclusionsXDR hypervirulent ST147 Kp is emerging, suggesting enhanced surveillance is essential.

Indexed as

Klebsiella InfectionsKlebsiella pneumoniaeAnti-Bacterial Agentsbeta-LactamasesHumansKlebsiellaPlasmidsRetrospective StudiesAnti-Bacterial Agentsbeta-LactamasesBla OXA-48Extensively drug resistantFusion plasmidHypervirulent Klebsiella pneumoniaeST147

Identifiers

PMID36788555
PMCPMC9927049
OpenAlexW4320856880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.